Hitoshi Ito1, Hiroshi Yaegashi2, Yoshiyuki Okada3, Takafumi Shimada2, Toshihide Yamaoka4, Kazutoshi Okubo3, Takashi Sakamoto1, Atsushi Mizokami2. 1. Department of Radiation Oncology, Kyoto Katsura Hospital, Kyoto, Japan. 2. Department of Integrative Cancer Therapy and Urology, Kanazawa University,Graduate School of Medical Science, Kanazawa, Japan. 3. Department of Urology, Kyoto Katsura Hospital, Kyoto, Japan. 4. Department of Diagnostic Imaging & Interventional Radiology, Kyoto Katsura Hospital, Kyoto, Japan.
Abstract
Background/Aim: Radium-223 therapy prolongs overall survival in castration-resistant prostate cancer (CRPC) patients with bone metastasis. Patients who are unable to complete six courses of radium-223 therapy reportedly have a poor prognosis. This study aimed to develop a risk score using the discontinuation factors of the above therapy modality. Patients and Methods: Seventy patients who received radium-223 therapy for metastatic CRPC at two Japanese Institutions were evaluated. Univariate and multivariate analyses were performed to identify the discontinuation factors and determine the risk scores. Results: The median survival time was 24.3 and 9.5 months in patients who did and did not complete the therapy, respectively. Multivariate analysis revealed haemoglobin and prostate-specific antigen as key factors. A risk score was developed using these factors, and patients were stratified into three groups. The discontinuation rate and survival after radium-223 therapy were significantly different. Conclusion: Our risk score may help evaluate the suitability of radium-223 in CRPC patients. Copyright 2021, International Institute of Anticancer Research.
Background/Aim: Radium-223 therapy prolongs overall survival in castration-resistant prostate cancer (CRPC) patients with bone metastasis. Patients who are unable to complete six courses of radium-223 therapy reportedly have a poor prognosis. This study aimed to develop a risk score using the discontinuation factors of the above therapy modality. Patients and Methods: Seventy patients who received radium-223 therapy for metastatic CRPC at two Japanese Institutions were evaluated. Univariate and multivariate analyses were performed to identify the discontinuation factors and determine the risk scores. Results: The median survival time was 24.3 and 9.5 months in patients who did and did not complete the therapy, respectively. Multivariate analysis revealed haemoglobin and prostate-specific antigen as key factors. A risk score was developed using these factors, and patients were stratified into three groups. The discontinuation rate and survival after radium-223 therapy were significantly different. Conclusion: Our risk score may help evaluate the suitability of radium-223 in CRPC patients. Copyright 2021, International Institute of Anticancer Research.
Authors: Fred Saad; Joan Carles; Silke Gillessen; Axel Heidenreich; Daniel Heinrich; Jeremy Gratt; Jérémy Lévy; Kurt Miller; Sten Nilsson; Oana Petrenciuc; Marcello Tucci; Manfred Wirth; Judith Federhofer; Joe M O'Sullivan Journal: Lancet Oncol Date: 2016-07-26 Impact factor: 41.316
Authors: Eleonora Dondossola; Stefano Casarin; Claudia Paindelli; Elena M De-Juan-Pardo; Dietmar W Hutmacher; Christopher J Logothetis; Peter Friedl Journal: J Natl Cancer Inst Date: 2019-10-01 Impact factor: 13.506
Authors: O Sartor; R E Coleman; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; N J Vogelzang; Ø Bruland; S Kobina; S Wilhelm; L Xu; M Shan; M W Kattan; C Parker Journal: Ann Oncol Date: 2017-05-01 Impact factor: 32.976